rose bengal sodium i-131
Trade name: Robengatope
Small moleculeapprovedImaging agent
Approved
Nov 23, 1971
Clinical trial activity
2 trials · 2 clinical orgs · 2 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 24, 2013 (NCT01760499)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
Radiopharmaceutical
Approval history
- approvedPriority reviewNov 23, 1971
Chemistry & pharmacology
Loading structure…
SMILES
OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C2=C3C=C([131I])C(=O)C([131I])=C3OC4=C2C=C([131I])C(O)=C4[131I]- Mol. weight
- 989.679 g/mol
- Imaging
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSMKF129JIZX ↗
- ChEMBLCHEMBL2218902 ↗
Also known as
- pv-10
- pv-10
- robengatope
- robengatope
- robengatope
- robengatope i-131
- rose bengal (131i) sodium
- rose bengal (131i) sodium
- rose bengal sodium (131i)
- rose bengal sodium (131i)
- rose bengal sodium i 131
- rose bengal sodium i 131
- rose bengal sodium i-131
- rose bengal sodium i-131
- rose bengal sodium i-131
- sodium rose bengal (131i)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02557321 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Provectus Biopharmaceuticals, Inc. |
| NCT01760499 | Phase 1 | Jan 24, 2013 | Provectus Biopharmaceuticals, Inc., University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Provectus Biopharmaceuticals, Inc. | For profit | 2 | 1 | 2 | 2013 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1